Growth Financing Recent $9M growth capital funding and investor activity signal strong capital availability and potential for expansion initiatives, presenting cross-sell opportunities for complementary medical devices or services.

Global Distribution Recent partnership with Australian Allografts as exclusive distributor for Navigator 2.0 Gamma Localization System in Australia indicates a willingness to expand channel partners and geographic reach, suggesting opportunities to onboard additional distributors or regional sales support.

Hemostasis & Cancer Portfolio Dilon focuses on hemostasis, cancer detection and assessment, and airway management, aligning with hospital procurement cycles for operating room efficiency, surgical hemostasis products, and sentinel node biopsy solutions—ideal for upsell in OR suites and cancer centers.

Strategic Partnerships Past and current collaborations (e.g., Xtant Medical, Allografts) demonstrate openness to co-development and bundled offerings, opening doors for joint marketing, bundled device packages, and integrated solution proposals to large health systems.

Clinical & Market Momentum Active press coverage and product launches since 2016, plus revenue scale, indicate momentum in the biosurgery and breast cancer treatment segments, suggesting targeting academic medical centers and high-volume cancer care networks for trials, pilots, and broader adoption.